Compugen (CGEN) Interest Coverage Ratio: History & Chart

Compugen Ltd.(CGEN)

Biotechnology · Holon, TA

$2.32+0.01 (+0.43%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About Compugen Ltd.

Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.

Holon, TA

75 employees

cgen.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Eran Ophir

View full financials

CGEN Interest Coverage Ratio Metrics

INTEREST COVERAGE RATIO

-38.30x

INTEREST COVERAGE RATIO AVG TTM

-38.48x

INTEREST COVERAGE RATIO AVG 3Y

-47.92x

INTEREST COVERAGE RATIO AVG 5Y

-37.39x

INTEREST COVERAGE RATIO AVG 10Y

-24.18x

INTEREST COVERAGE RATIO AVG 15Y

-21.44x

INTEREST COVERAGE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+0.47%

CURRENT VS 3Y AVG

+20.06%

CURRENT VS 5Y AVG

-2.43%

CURRENT VS 10Y AVG

-58.44%

CURRENT VS 15Y AVG

-78.64%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

-4.20x

median of 329 covered companies

CURRENT VS SECTOR MEDIAN

-812.01%

vs the sector median at left

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Compugen Ltd. (CGEN)	$219.36M	-38.30x	-38.48x	-47.92x	-37.39x
Alector, Inc. (ALEC)vs ›	$230.93M	N/A	N/A	N/A	N/A
Keros Therapeutics, Inc. (KROS)vs ›	$228.41M	N/A	N/A	N/A	N/A
Electra Therapeutics Inc. (ETRA)vs ›	$206.61M	N/A	N/A	N/A	N/A
AN2 Therapeutics, Inc. (ANTX)vs ›	$194.13M	N/A	N/A	N/A	N/A
Biodesix, Inc. (BDSX)vs ›	$238.51M	-3.60x	N/A	N/A	N/A
BioAge Labs Inc. (BIOA)vs ›	$242.46M	-133.11x	N/A	N/A	N/A
High Tide Inc. (HITI)vs ›	$239.89M	-1.08x	0.39x	0.39x	0.20x
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$192.97M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$241.70M	0.97x	0.97x	0.97x	0.97x

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Compugen Ltd. (CGEN)

$219.36M

-38.30x

-38.48x

-47.92x

-37.39x

Alector, Inc. (ALEC)vs ›

$230.93M

N/A

Keros Therapeutics, Inc. (KROS)vs ›

$228.41M

N/A

Electra Therapeutics Inc. (ETRA)vs ›

$206.61M

N/A

AN2 Therapeutics, Inc. (ANTX)vs ›

$194.13M

N/A

Biodesix, Inc. (BDSX)vs ›

$238.51M

-3.60x

N/A

BioAge Labs Inc. (BIOA)vs ›

$242.46M

-133.11x

N/A

High Tide Inc. (HITI)vs ›

$239.89M

-1.08x

0.39x

0.20x

Eledon Pharmaceuticals, Inc. (ELDN)vs ›

$192.97M

N/A

Akebia Therapeutics, Inc. (AKBA)vs ›

$241.70M

0.97x

Interest Coverage Ratio FAQ

What is the interest coverage ratio for Compugen Ltd. (CGEN)?

The interest coverage ratio for CGEN stock is -38.30x.

Is Compugen Ltd.'s interest coverage ratio high or low?

The interest coverage ratio of -38.30x is in line with its 5-year average of -37.39x, around the middle of its 5-year range (-115.57x–10.45x).

What is the TTM average interest coverage ratio for Compugen Ltd. (CGEN)?

The TTM average interest coverage ratio for CGEN stock is -38.48x.

What is the 3Y average interest coverage ratio for Compugen Ltd. (CGEN)?

The 3Y average interest coverage ratio for CGEN stock is -47.92x.

What is the 5Y average interest coverage ratio for Compugen Ltd. (CGEN)?

The 5Y average interest coverage ratio for CGEN stock is -37.39x.

What is the 10Y average interest coverage ratio for Compugen Ltd. (CGEN)?

The 10Y average interest coverage ratio for CGEN stock is -24.18x.

What is the 15Y average interest coverage ratio for Compugen Ltd. (CGEN)?

The 15Y average interest coverage ratio for CGEN stock is -21.44x.

DATE	INTEREST COVERAGE RATIO
2019-09-30	-38.30x
2019-06-30	-22.75x
2019-03-31	-80.32x
2018-12-31	-35.97x
2018-09-30	-15.08x
2018-06-30	-59.05x
2018-03-31	10.45x
2017-12-31	-38.31x
2017-09-30	-92.40x
2017-06-30	-42.66x
2017-03-31	-115.57x
2016-12-31	-59.44x
2016-09-30	-42.83x
2016-06-30	-65.50x
2016-03-31	-32.86x
2015-12-31	-2.85x
2015-09-30	-40.20x
2015-06-30	-47.95x
2015-03-31	-35.32x
2014-12-31	-0.83x
2014-09-30	-5.73x
2014-06-30	-3.13x
2014-03-31	-2.34x
2013-12-31	-2.04x
2013-09-30	-23.79x
2013-03-31	-6.72x
2012-12-31	-3.18x
2012-09-30	-31.79x
2012-06-30	-1.27x
2012-03-31	-3.12x
2011-12-31	-2.32x
2011-09-30	-6.28x
2011-06-30	-2.77x
2011-03-31	-8.28x
2010-12-31	-20.72x
2010-09-30	-6.16x
2010-06-30	-22.85x
2010-03-31	-2718.00x
2009-12-31	-12.84x
2009-09-30	-11.18x
2009-06-30	-5.52x
2009-03-31	-8.70x
2005-12-31	-17.19x

DATE

INTEREST COVERAGE RATIO

2019-09-30

-38.30x

2019-06-30

-22.75x

2019-03-31

-80.32x

2018-12-31

-35.97x

2018-09-30

-15.08x

2018-06-30

-59.05x

2018-03-31

10.45x

2017-12-31

-38.31x

2017-09-30

-92.40x

2017-06-30

-42.66x

2017-03-31

-115.57x

2016-12-31

-59.44x

2016-09-30

-42.83x

2016-06-30

-65.50x

2016-03-31

-32.86x

2015-12-31

-2.85x

2015-09-30

-40.20x

2015-06-30

-47.95x

2015-03-31

-35.32x

2014-12-31

-0.83x

2014-09-30

-5.73x

2014-06-30

-3.13x

2014-03-31

-2.34x

2013-12-31

-2.04x

2013-09-30

-23.79x

2013-03-31

-6.72x

2012-12-31

-3.18x

2012-09-30

-31.79x

2012-06-30

-1.27x

2012-03-31

-3.12x

2011-12-31

-2.32x

2011-09-30

-6.28x

2011-06-30

-2.77x

2011-03-31

-8.28x

2010-12-31

-20.72x

2010-09-30

-6.16x

2010-06-30

-22.85x

2010-03-31

-2718.00x

2009-12-31

-12.84x

2009-09-30

-11.18x

2009-06-30

-5.52x

2009-03-31

-8.70x

2005-12-31

-17.19x

Interest Coverage Ratio: -38.30x

CGEN Interest Coverage Ratio

CGEN Average Interest Coverage Ratio Chart

CGEN Current vs Average Interest Coverage Ratio Chart

CGEN Interest Coverage Ratio Metrics

CGEN Competitors' Interest Coverage Ratio

Financial Health Indicators

Interest Coverage Ratio Formula & Definition

Interest Coverage Ratio FAQ

CGEN Interest Coverage Ratio History

Related Metrics